Cargando…

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib

Detalles Bibliográficos
Autores principales:	Tchekmedyian, Nishan, Paxton, Bill, Lebel, Francois, Keossayan, Lena, Heymach, John V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474396/ https://www.ncbi.nlm.nih.gov/pubmed/34589960 http://dx.doi.org/10.1016/j.jtocrr.2020.100081

Ejemplares similares

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
por: Le, Xiuning, et al.
Publicado: (2022)

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
por: Kalra, Rashi, et al.
Publicado: (2022)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Oldenburg, Reid, et al.
Publicado: (2021)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021)

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
por: Wang, Shuanghu, et al.
Publicado: (2023)

Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness
por: Lee, Heejin, et al.
Publicado: (2020)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
por: Zhou, Shan, et al.
Publicado: (2023)

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method
por: Wang, Jinhui, et al.
Publicado: (2021)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective
por: Lee, Chee Khoon, et al.
Publicado: (2023)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

HER2在NSCLC中的作用
Publicado: (2015)

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer
por: James, N D, et al.
Publicado: (2001)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
por: Prelaj, Arsela, et al.
Publicado: (2022)

Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
por: Perng, Pang-Shuo, et al.
Publicado: (2023)

Structure-based classification predicts drug response in EGFR-mutant NSCLC
por: Robichaux, Jacqulyne P., et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report
por: Takayasu, Hirokazu, et al.
Publicado: (2023)

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
por: Zhang, Yongchao, et al.
Publicado: (2020)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Second-line treatment for primary central nervous system lymphoma
por: Reni, M, et al.
Publicado: (1999)

Prolonged Survival of Acute Lymphoblastic Leukemia with Intrathecal Treatments for Isolated Central Nervous System Relapse
por: Gorshein, Elan, et al.
Publicado: (2018)

Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System
por: Liu, Yuxin, et al.
Publicado: (2019)

In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
por: Alamery, Salman, et al.
Publicado: (2023)

A sart1 Zebrafish Mutant Results in Developmental Defects in the Central Nervous System
por: Henson, Hannah E., et al.
Publicado: (2020)

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
por: Riudavets, M., et al.
Publicado: (2021)

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
por: Yan, Dan
Publicado: (2023)

SBRT for centrally localized NSCLC – What is too central?
por: Roesch, J., et al.
Publicado: (2016)

Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
por: Lister, T. A., et al.
Publicado: (1977)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
por: Ho, Gwo-Fuang, et al.
Publicado: (2019)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aickcgj1bbs3d30apevri6mnhv